IMGT (XKRX:456570) Current Deferred Taxes Liabilities : ₩0.00 Mil (As of Dec. 2023)

View and export this data going back to 2023. Start your Free Trial

What is IMGT Current Deferred Taxes Liabilities?

Current Deferred Taxes Liabilities represent future tax liabilities, resulting from temporary differences between book (accounting) value of assets and liabilities and their tax value, or timing differences between the recognition of gains and losses in financial statements and their recognition in a tax computation. Deferred tax liabilities generally arise where tax relief is provided in advance of an accounting expense, or income is accrued but not taxed until received.

IMGT's current deferred tax liabilities for the quarter that ended in Dec. 2023 was ₩0.00 Mil.

IMGT Current Deferred Taxes Liabilities Historical Data

The historical data trend for IMGT's Current Deferred Taxes Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

IMGT Current Deferred Taxes Liabilities Chart

IMGT Annual Data

Trend

Dec20

Dec21

Dec22

Dec23

Current Deferred Taxes Liabilities

IMGT Semi-Annual Data
	Dec20	Dec21	Dec22	Dec23
Current Deferred Taxes Liabilities	-	-	-	-

IMGT Current Deferred Taxes Liabilities Related Terms

Thank you for viewing the detailed overview of IMGT's Current Deferred Taxes Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.

IMGT Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » IMGT Corp Ltd (XKRX:456570) » Definitions » Current Deferred Taxes Liabilities

Comparable Companies

Traded in Other Exchanges

N/A

Address

172 Dolma-ro,, 408, Healthcare Innovation Park, Bundang-gu, Gyeonggi-do, Seongnam-si, KOR, 13605

Website

http://www.imgt.co.kr

IMGT Corp Ltd develops a focused ultrasound-based drug delivery platform for intractable diseases. It is developing nanomedicines and focused ultrasound medical devices that respond to focused ultrasound. The firm has two pipeline products IMD20 and IMP101. IMD20 is a FUS device developed for chronic pain as a product with reduced size and output from IMD10 developed for cancer treatment. IMP101 is a nanoparticle used for hepatocarcinoma embolization.

IMGT Headlines

No Headlines